Relationship between GOLM1 expression level and sensitivity to endocrine therapy in ER-positive breast cancer
10.3760/cma.j.cn.115807-20221118-00330
- VernacularTitle:GOLM1表达水平与ER阳性乳腺癌对内分泌治疗敏感性的关系
- Author:
Xiangjuan LIU
1
;
Jiahong ZHANG
;
Jian ZHANG
;
Hongyan ZANG
Author Information
1. 烟台市烟台山医院乳腺外科,烟台 264003
- Keywords:
Breast cancer;
Golgi membrane protein 1;
Tamoxifen;
Estrogen Receptor
- From:
Chinese Journal of Endocrine Surgery
2023;17(4):499-503
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the relationship between Golgi membrane protein 1 (GOLM1) expression and the sensitivity of estrogen receptor (ER) positive breast cancer to endocrine therapy.Methods:Tamoxifen (TAM) -resistant ER-positive breast cancer cells were established, and the expression of GOLM1 in these cells was detected. The expression level of GOLM1 in the cells was regulated, and the effects of GOLM1 expression on cell proliferation and colony formation were detected by MTT and colony formation assay, respectively. Western blot was used to detect the effect of GOLM1 expression on the expression of drug resistance proteins P-gp and MRP1. Breast cancer patients recruited for endocrine therapy and patients without endocrine therapy were divided into high GOLM1 expression group and low GOLM1 expression group, and the effect of GOLM1 expression level on the survival rate of the two groups of patients was observed.Results:Colony formation assay showed that after TAM treatment, the colony formation ability of TAM-resistant MCF-7 cells was significantly higher than that of TAM-sensitive McF-7 cells (all P<0.05). The expression level of GOLM1 in MCF-7R cells (2.31±0.18) was higher than that in MCF-7 cells (1±0.10) ( t=11.02, P<0.001). Knockdown of GOLM1 in MCF-7R cells decreased the cell proliferation and colony formation ability, and the expression of drug resistance proteins P-gp and MRP1 also decreased (all P<0.05). The survival rate of patients with high GOLM1 expression was lower than that of patients with low GOLM1 expression after endocrine therapy ( χ2=5.45, P=0.020). In patients without endocrine therapy, there was no significant difference in survival between patients with high and low GOLM1 expression ( χ2=1.49, P=0.223) . Conclusion:High expression of GOLM1 is significantly associated with decreased sensitivity to endocrine therapy in ER-positive breast cancer patients.
